Rofumilast, a novel phosphodiesterase 4 inhibitor, for COPD patients with a history of exacerbations

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

Volumn 5, Issue 1, 2011, Pages 57-70

  Field, Stephen K ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Acute exacerbations; Chronic bronchitis; COPD; Phosphodiesterase 4 inhibitor; Rofumilast

Indexed keywords

AMPICILLIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CORTICOSTEROID; COTRIMOXAZOLE; DOXYCYCLINE; DRUG METABOLITE; FLUVOXAMINE; GLUCOSE; HEMOGLOBIN A1C; LONG ACTING DRUG; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PREDNISOLONE; RIFAMPICIN; ROFLUMILAST; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE LUNG DISEASE; ADD ON THERAPY; AIRWAY OBSTRUCTION; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; GENDER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOSPITALIZATION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LUNG FUNCTION; MEDIATOR RELEASE; MENTAL DISEASE; MONOTHERAPY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PNEUMONIA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SMOKING; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNDERWEIGHT; VOMITING; WEIGHT REDUCTION;

EID: 80555146482     PISSN: 11795484     EISSN: 11795484     Source Type: Journal    
DOI: 10.4137/CCRPM.S7049     Document Type: Review

References (84)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. http://www.nhlbi.goldcopd.org.
2. Salvi S, Barnes PJ. Is exposure to biomass smoke the biggest risk factor for COPD globally? Chest. 2010;138:3-6.
3. Hogg JC, Chu F, Utokaparach S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. New Engl J Med. 2004;350(26): 2645-53.
4. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J. 2007;14(Suppl B):B5-B32.
5. Saetta M, di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:822-6.
6. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic infammation: a systematic review and a meta-analysis. Thorax. 2004;59:574-80.
7. Barnes PJ. The cytokine network in COPD. Am J Respir Cell Mol Biol. 2009; 41(6):631-8.
8. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008; 31:869-73.
9. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165-85.
10. Wedzicha JA, Seemungal TAR. COPD exacerbations: defning their cause and prevention. Lancet. 2007;370:786-96.
11. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-52.
12. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418-22.
13. Chapman KR, Bhutani M, Bourbeau J, et al. The hospital burden of COPD in Canada. Am J Respir Crit Care Med. 2010;181:A1500.
14. Hoogendoorn M, Hoogenveen RT, Rutten-van Molken MP, Vestbo J, Feenstra TL. Case fatality of COPD exacerbations: a meta-analysis and statistical modeling approach. Eur Respir J. 2011;37:508-15.
15. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;154:959-67.
16. Nie JX, Wang L, Upshur REG. Mortality of elderly patients in Ontario after admission for chronic obstructive pulmonary disease. Can Respir J. 2007; 14:485-9.
17. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New Engl J Med. 2010;363: 1128-38.
18. Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135:975-82.
19. Miravitlles M, Guerrero T, Mayordomo C, et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration. 2000;67:495-501.
20. Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest. 2007;131:20-28.
21. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;4:554-64.
22. Sethi S, Evans N, Grant BJB, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. New Engl J Med. 2002;347:465-7.
23. Sethi S, Wrona C, Grant BJB, Murphy TF. Strain-specifc immune response to Haemophilus infuenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:448-53.
24. Tager I, Speizer FE. Role of infection in chronic bronchitis. New Engl J Med. 1975;292:563-71.
25. Anthonisen NR, Manfreda J, Warren CP, Hershfeld ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
26. Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. New Engl J Med. 2003;348:2618-25.
27. Rabe KF, Bateman ED, O'Donnell DE, Witte S, Bredenbroker D, Bethke TD. Rofumilast-an oral anti-infammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 2005;366(5):63-71.
28. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New Engl J Med. 2011;364: 1093-1103.
29. Calverley PM, Pauwels R, Vestbo J, et al. Combined salmeterol and futicasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 2003;361:449-56.
30. Szrafranski W, Cukier A, Ramirez A, et al. Effcacy and safety of budesonide/ formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74-81.
31. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and futicasone propionate and survival in chronic obstructive pulmonary disease. New Engl J Med. 2007;356:775-89.
32. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New Engl J Med. 2008;359:1543-54.
33. Welte T, Miravitlles M, Hernandez P, et al. Effcacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180: 741-50.
34. Vestbo J, Srensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353:1819-23.
35. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New Engl J Med. 1999;340: 1948-53.
36. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised, placebo-controlled trial of inhaled futicasone propionate in patients with chronic obstructive pulmonary disease. Lancet. 1998;351:773-80.
37. Burge P, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of futicasone proprionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297-303.
38. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005;60;992-7.
39. Suissa S, Ernst P, Vandemheen, Aaron SD. Methodological issues in therapeutic trials in COPD. Eur Respir J. 2008;31:927-33.
40. Wouters EFM, Postma DS, Fokkens B, et al. Withdrawal of futicasone propionate from combined salmeterol/futicasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomized controlled trial. Thorax. 2005;60:480-7.
41. Aaron SD, Vandenheem KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or futicasone-salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med. 2007;146:545-55.
42. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and read-mission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:580-4.
43. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease. Immortal time bias in observational studies. Am J Respir Crit Care Med. 2003;168:49-53.
44. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 173:842-6.
45. Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J. 2004;23:391-5.
46. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk for hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176:162-6.
47. Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med. 2011;183:675-8.
48. Calverley PMA, Rennard SI. What have we learned from large treatment trials in COPD? Lancet. 2007;370:774-85.
49. Wedzicha JA, Calverley PMA, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/futicasone propionate ortiotropium bromide. Am J Respir Crit Care Med. 2008;177:19-26.
50. Barnes PJ. Theophylline. New perspectives for an old drug. Am J Respir Crit Care Med. 2003;167:813-8.
51. Barnes PJ. Theophylline for COPD. Thorax. 2006;61:742-3.
52. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488-520.
53. Giembycz MA, Field SK. Rofumilast: frst phosphodiesterase inhibitor approved for treatment of COPD. Drug, Design, Development and Therapy. 2010;4:147-158.
54. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 1998;157:351-70.
55. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation. 2004;110: 3149-55.
56. Souness JE, Aldous D, Sargent C. Immunosuppressive and anti-infammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology. 2000;47:127-62.
57. Spina D. Phosphodiesterase-4 inhibitors in the treatment of infammatory lung disease. Drugs. 2003;63:2575-94.
58. Rennard SI, Schacter N, Strek M, Rickard K, Amit O. Cilomilast for COPD: results of the 6-month, placebo controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest. 2006;129:55-66.
59. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005;365:167-75.
60. European Medicines Agency. DAXAS. Rofumilast. www.ema.europa.eu/docs/en_GB/document_library/EPA_summary_for_the_public/human/001179/WC500095211.pdf.
61. Field SK. Rofumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma. Expert Opin Investig Drugs. 2008;17: 811-8.
62. Hatzelmann A, Schudt C. Anti-infammatory and immunomodulatory potential of the novel PDE4 inhibitor rofumilast in vitro. J Pharmacol Exp Ther. 2001;297:267-79.
63. Calverley PMA, Rabe KF, Goehring U-M, Kristiansen S, Fabbri LM, Martinez FJ. Rofumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet. 2009;374:684-95.
64. David M, Zech K, Seiberling M, Weimar C, Bethke TD. Rofumilast, a novel, oral, selective PDE4 inhibitor, shows high absolute bioavailability. J Allergy Clin Immunol. 2004;113:S220-S221.
65. Nassr N, Hunnemeyer A, Herzog R, et al. Effects of rifampicin on the pharmacokinetics of rofumilast and rofumilast N-oxide inhealthy subjects. Br J Clin Pharmacol. 2009;68:580-7.
66. Sanz M-J, Cortijo J, Taha MA, et al. Rofumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br J Pharmacol. 2007;152:481-92.
67. Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G. Rofumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med. 2005;172:848-53.
68. Martorana PA, Lunghi B, Lucattelli M, De Cunto G, Beume R, Lungarella G. Effect of rofumilast on infammatory cells in the lungs of cigarette-exposed mice. BMC Pulm Med. 2008;8:17.
69. Fitz Gerald MF, Spicer D, McAulay AE, Wollin L, Beume R. Rofumilast but not methylprednisolone inhibited cigarette-smoke-induced pulmonary infammation in guinea pigs. Eur Respir J. 2006;28(Suppl 50):663S.
70. Grootendorst DC, Gauw SA, Verhoosel RM, et al. The PDE4 inhibitor rofumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Thorax. 2007;62:1081-7.
71. Bredenbroker D, Syed J, Leichtl S, Rathgeb F, Wurst W. Rofumilast, a new orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease. Eur Respir J. 2002; 20 (Suppl 38)374S.
72. Boszormenyi-Nagy G, Pieters WR, Steffen H, et al. The effect of rofumilast treatment and subsequent withdrawal in patients with COPD. Am J Respir Crit Care Med. 2005;169:A544.
73. Calverley PMA, Sanchez-Toril F, McIvor RA, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with rofumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:154-61.
74. Rennard SI, Calverley PMA, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor rofumilast-the importance of defning different subsets of patients with COPD. Respiratory Research 2011,12:18. http://respiratory-research.com/12/1/18.
75. Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, et al. Rofumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomized clinical trials. Lancet. 2009; 374:695-703.
76. Chong J, Poole P, Leung B, Black PN. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011 May 11;5:CD002309. The Cochrane Collaboration 2011, Issue 5. http://www.thecochranelibrary.com.
77. Calverley PMA, Martinez F, Goehring U, et al. Defning patient populations in COPD: experience with rofumilast. COPD 7, June 30-July 2, 2010, Birmingham, UK. A48;abstract.
78. Wouters E, Teichmann P, Brose M, Fabbri LM, Rabe KF. Effect of rofumilast on glucose levels in patients with COPD and diabetes mellitus type 2. Eur Respir J 2010:P4002. http://www.ersnet.org/learning_resources_player/abstract_print_10/main_frameset.htm.
79. Wouters EFM, Teichmann P, Brose M, Goke B, Rabe KF, Fabbri LM. Effects of rofumilast, a phosphodiesterase 4 inhibitor, on glucose homeostasis in patients with treatment-naive diabetes (type 2). Am J Respir Crit Care Med. 2010;181:A4471.
80. Calverley PMA, Fabbri LM, Rabe KF, Mosberg H. Rofumilast in the treatment of COPD: a pooled safety analysis. Eur Respir J. 2010: abstract P4001. http://www.ersnet.org/learning_resources_player/abstract_print_10/main_frameset.htm.
81. Martinez FJ, Rabe KF, Wouters EFM, et al. Time course and reversibility of weight decrease with rofumilast, a phosphodiesterase 4 inhibitor. Am J Respir Crit Care Med. 2010;181:A4441.
82. Wollin L, Bundschuh DS, Wohlsen A, et al. Inhibition of airway hyperresponsiveness and pulmonary infammation by rofumilast and other PDE4 inhibitors. Pulm Pharmacol Ther. 2006;19:343-52.
83. Bateman ED, Calverley PMA, Fabbri LM, et al. Effcacy of rofumilast in patients with a history of frequent exacerbations: pooled data from pivotal 12-month studies. Eur Respir J. 2010: abstract P4003 http://www.ersnet.org/learning_resources_player/abstract_print_10/main_frameset.htm.
84. Rutten-van Molken MPMH, van Nooten FE, Lindemann M, Caeser M, Calverley PMA. A 1-year prospective cost-effectiveness analysis of rofumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics. 2007;25:695-711.